| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Y Chromosome | 38 | 2009 | 43 | 3.150 |
Why?
|
| Spermatogenesis | 21 | 2017 | 47 | 2.890 |
Why?
|
| Nursing Homes | 15 | 2014 | 42 | 2.050 |
Why?
|
| Mice | 75 | 2019 | 2511 | 1.920 |
Why?
|
| Organoids | 10 | 2020 | 98 | 1.860 |
Why?
|
| Testis | 22 | 2018 | 65 | 1.740 |
Why?
|
| Transcription Factors | 15 | 2021 | 176 | 1.360 |
Why?
|
| Proteins | 13 | 2009 | 142 | 1.300 |
Why?
|
| Chromosome Mapping | 24 | 2013 | 193 | 1.210 |
Why?
|
| Animals | 87 | 2019 | 7569 | 1.210 |
Why?
|
| Homes for the Aged | 6 | 2014 | 20 | 1.150 |
Why?
|
| Mutation | 20 | 2015 | 493 | 1.140 |
Why?
|
| X Chromosome | 17 | 2007 | 27 | 1.010 |
Why?
|
| Organizational Culture | 3 | 2014 | 25 | 0.910 |
Why?
|
| Infertility, Male | 5 | 2005 | 24 | 0.890 |
Why?
|
| Mice, Mutant Strains | 11 | 2013 | 49 | 0.870 |
Why?
|
| DNA Transposable Elements | 4 | 2013 | 13 | 0.820 |
Why?
|
| Male | 82 | 2018 | 19642 | 0.780 |
Why?
|
| Mice, Transgenic | 14 | 2019 | 258 | 0.770 |
Why?
|
| High Mobility Group Proteins | 5 | 2007 | 7 | 0.750 |
Why?
|
| Fibroblasts | 4 | 2021 | 114 | 0.750 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2014 | 104 | 0.730 |
Why?
|
| Medicare | 8 | 2002 | 213 | 0.730 |
Why?
|
| Home Care Services | 7 | 1999 | 53 | 0.690 |
Why?
|
| RNA-Binding Proteins | 6 | 2017 | 69 | 0.680 |
Why?
|
| Liver | 7 | 2020 | 492 | 0.670 |
Why?
|
| Health Expenditures | 4 | 2009 | 68 | 0.650 |
Why?
|
| Humans | 76 | 2021 | 32799 | 0.640 |
Why?
|
| Molecular Sequence Data | 28 | 2013 | 352 | 0.620 |
Why?
|
| MicroRNAs | 2 | 2018 | 188 | 0.600 |
Why?
|
| Mutagenesis, Insertional | 3 | 2007 | 15 | 0.580 |
Why?
|
| Endopeptidases | 5 | 2015 | 26 | 0.580 |
Why?
|
| Necrosis | 1 | 2018 | 51 | 0.570 |
Why?
|
| Patient-Centered Care | 3 | 2014 | 72 | 0.570 |
Why?
|
| Spermatogonia | 3 | 2003 | 14 | 0.540 |
Why?
|
| Female | 58 | 2016 | 20262 | 0.530 |
Why?
|
| Animal Use Alternatives | 1 | 2017 | 3 | 0.520 |
Why?
|
| Culture Techniques | 1 | 2017 | 14 | 0.520 |
Why?
|
| Insulin | 3 | 2018 | 367 | 0.520 |
Why?
|
| Amniotic Fluid | 3 | 2013 | 86 | 0.510 |
Why?
|
| Inflammation | 2 | 2018 | 536 | 0.510 |
Why?
|
| Base Sequence | 23 | 2013 | 247 | 0.510 |
Why?
|
| Mice, Inbred C57BL | 17 | 2012 | 789 | 0.500 |
Why?
|
| Stem Cells | 5 | 2013 | 314 | 0.500 |
Why?
|
| Nicotinamide-Nucleotide Adenylyltransferase | 2 | 2013 | 5 | 0.490 |
Why?
|
| Embryo, Mammalian | 2 | 2012 | 28 | 0.470 |
Why?
|
| Membrane Proteins | 2 | 2013 | 251 | 0.460 |
Why?
|
| Mitochondrial Proteins | 4 | 2012 | 71 | 0.450 |
Why?
|
| Blotting, Western | 4 | 2010 | 287 | 0.450 |
Why?
|
| H-Y Antigen | 9 | 2000 | 9 | 0.450 |
Why?
|
| Spodoptera | 1 | 2014 | 4 | 0.450 |
Why?
|
| Baculoviridae | 1 | 2014 | 6 | 0.450 |
Why?
|
| Lab-On-A-Chip Devices | 4 | 2020 | 29 | 0.450 |
Why?
|
| Personnel Selection | 2 | 2014 | 12 | 0.440 |
Why?
|
| United States | 29 | 2014 | 4109 | 0.430 |
Why?
|
| Genetic Engineering | 1 | 2014 | 18 | 0.420 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 2 | 2014 | 7 | 0.420 |
Why?
|
| Policy Making | 1 | 2014 | 19 | 0.420 |
Why?
|
| Sperm-Ovum Interactions | 1 | 2013 | 3 | 0.420 |
Why?
|
| Fertilization | 1 | 2013 | 5 | 0.420 |
Why?
|
| Immunoglobulins | 1 | 2013 | 13 | 0.420 |
Why?
|
| Organizational Innovation | 1 | 2014 | 31 | 0.410 |
Why?
|
| Serum Albumin | 1 | 2014 | 57 | 0.410 |
Why?
|
| Workplace | 1 | 2014 | 50 | 0.410 |
Why?
|
| Nuclear Proteins | 6 | 2003 | 76 | 0.390 |
Why?
|
| Nucleotidyltransferases | 1 | 2012 | 8 | 0.390 |
Why?
|
| Gene Expression Regulation, Developmental | 5 | 2013 | 67 | 0.390 |
Why?
|
| Axons | 1 | 2012 | 33 | 0.380 |
Why?
|
| Receptors, G-Protein-Coupled | 6 | 2019 | 84 | 0.380 |
Why?
|
| Spermatozoa | 3 | 2004 | 28 | 0.370 |
Why?
|
| Job Satisfaction | 2 | 2009 | 41 | 0.370 |
Why?
|
| Ribonucleoproteins, Small Nucleolar | 3 | 2009 | 4 | 0.360 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2011 | 24 | 0.360 |
Why?
|
| Immunity | 1 | 2011 | 20 | 0.360 |
Why?
|
| Antibodies | 3 | 2010 | 51 | 0.350 |
Why?
|
| Amino Acid Sequence | 17 | 2013 | 282 | 0.350 |
Why?
|
| DNA-Binding Proteins | 7 | 2000 | 142 | 0.330 |
Why?
|
| Mitochondria | 3 | 2011 | 206 | 0.330 |
Why?
|
| Audiology | 1 | 2010 | 1 | 0.320 |
Why?
|
| Cell Differentiation | 3 | 2010 | 467 | 0.320 |
Why?
|
| Hearing Loss, Unilateral | 1 | 2010 | 3 | 0.320 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2010 | 22 | 0.320 |
Why?
|
| Pharmaceutical Preparations | 2 | 2021 | 37 | 0.320 |
Why?
|
| Embryonic Stem Cells | 1 | 2010 | 28 | 0.320 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2010 | 18 | 0.320 |
Why?
|
| Ovary | 2 | 2012 | 58 | 0.310 |
Why?
|
| Employment | 3 | 2014 | 51 | 0.310 |
Why?
|
| Sex Differentiation | 3 | 2008 | 5 | 0.310 |
Why?
|
| Phenotype | 8 | 2013 | 638 | 0.310 |
Why?
|
| HIV-1 | 1 | 2009 | 45 | 0.300 |
Why?
|
| Medical Assistance | 1 | 2009 | 3 | 0.300 |
Why?
|
| State Health Plans | 1 | 2009 | 5 | 0.300 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2009 | 5 | 0.300 |
Why?
|
| Cost Sharing | 1 | 2009 | 10 | 0.300 |
Why?
|
| Hepatocytes | 2 | 2021 | 82 | 0.300 |
Why?
|
| Mitochondrial Membranes | 2 | 2011 | 24 | 0.290 |
Why?
|
| Prescription Drugs | 1 | 2009 | 19 | 0.290 |
Why?
|
| Cost Control | 5 | 2009 | 18 | 0.290 |
Why?
|
| Transgenes | 4 | 2005 | 49 | 0.290 |
Why?
|
| Tissue Scaffolds | 3 | 2016 | 421 | 0.290 |
Why?
|
| Sequence Analysis, DNA | 7 | 2013 | 135 | 0.290 |
Why?
|
| Infertility | 2 | 2007 | 14 | 0.280 |
Why?
|
| Chromosomes, Mammalian | 1 | 2008 | 13 | 0.280 |
Why?
|
| Sexual Behavior, Animal | 1 | 2008 | 8 | 0.280 |
Why?
|
| Aggression | 1 | 2008 | 30 | 0.280 |
Why?
|
| Ovarian Neoplasms | 1 | 2009 | 103 | 0.280 |
Why?
|
| Genes, sry | 2 | 2005 | 2 | 0.280 |
Why?
|
| Octamer Transcription Factor-3 | 3 | 2014 | 20 | 0.270 |
Why?
|
| Gene Expression | 5 | 2009 | 334 | 0.270 |
Why?
|
| Serotonin Uptake Inhibitors | 2 | 2004 | 37 | 0.270 |
Why?
|
| Cloning, Molecular | 11 | 2002 | 73 | 0.270 |
Why?
|
| Rats | 4 | 2013 | 1606 | 0.270 |
Why?
|
| Gene Deletion | 5 | 2013 | 65 | 0.260 |
Why?
|
| Tissue Engineering | 5 | 2021 | 659 | 0.260 |
Why?
|
| Biosensing Techniques | 2 | 2017 | 25 | 0.260 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 188 | 0.250 |
Why?
|
| Toxicity Tests | 2 | 2017 | 13 | 0.250 |
Why?
|
| Prospective Payment System | 4 | 1999 | 9 | 0.240 |
Why?
|
| Animals, Genetically Modified | 3 | 2014 | 67 | 0.240 |
Why?
|
| SOX9 Transcription Factor | 5 | 2007 | 12 | 0.240 |
Why?
|
| Signal Transduction | 3 | 2019 | 686 | 0.240 |
Why?
|
| Fertility | 3 | 2004 | 23 | 0.230 |
Why?
|
| Serotonin | 2 | 2004 | 37 | 0.230 |
Why?
|
| Genomic Imprinting | 1 | 2004 | 3 | 0.220 |
Why?
|
| Transcription, Genetic | 6 | 2001 | 134 | 0.220 |
Why?
|
| Loudness Perception | 1 | 2004 | 1 | 0.220 |
Why?
|
| Otoacoustic Emissions, Spontaneous | 1 | 2004 | 2 | 0.220 |
Why?
|
| Ligases | 4 | 2003 | 4 | 0.220 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2004 | 7 | 0.220 |
Why?
|
| Aged, 80 and over | 6 | 2014 | 4032 | 0.220 |
Why?
|
| Depression | 2 | 2004 | 448 | 0.210 |
Why?
|
| Testicular Hormones | 2 | 2005 | 2 | 0.210 |
Why?
|
| Genetic Markers | 5 | 2000 | 125 | 0.210 |
Why?
|
| Wounds and Injuries | 2 | 2006 | 245 | 0.210 |
Why?
|
| Postural Balance | 1 | 2016 | 180 | 0.210 |
Why?
|
| Aged | 12 | 2016 | 10538 | 0.210 |
Why?
|
| In Situ Hybridization | 7 | 2005 | 37 | 0.210 |
Why?
|
| Superoxides | 3 | 2015 | 19 | 0.210 |
Why?
|
| Pesticides | 1 | 2016 | 196 | 0.200 |
Why?
|
| Cell Culture Techniques | 3 | 2020 | 172 | 0.200 |
Why?
|
| Pedigree | 4 | 2005 | 140 | 0.200 |
Why?
|
| Occupational Exposure | 1 | 2016 | 231 | 0.200 |
Why?
|
| Genes, Dominant | 4 | 2005 | 27 | 0.200 |
Why?
|
| Mice, Inbred C3H | 6 | 2004 | 27 | 0.200 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 240 | 0.190 |
Why?
|
| Germ Cells | 1 | 2002 | 10 | 0.190 |
Why?
|
| Fee-for-Service Plans | 1 | 2002 | 12 | 0.190 |
Why?
|
| Health Services for the Aged | 1 | 2002 | 25 | 0.190 |
Why?
|
| Transients and Migrants | 1 | 2016 | 298 | 0.190 |
Why?
|
| Sequence Deletion | 6 | 2003 | 38 | 0.190 |
Why?
|
| Economic Competition | 2 | 1996 | 9 | 0.190 |
Why?
|
| SOXB1 Transcription Factors | 2 | 2014 | 18 | 0.190 |
Why?
|
| Sequence Homology, Nucleic Acid | 5 | 2004 | 18 | 0.190 |
Why?
|
| Oxidative Stress | 4 | 2015 | 239 | 0.190 |
Why?
|
| Efficiency, Organizational | 2 | 1999 | 19 | 0.180 |
Why?
|
| Liver Cirrhosis | 2 | 2019 | 82 | 0.180 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2002 | 3 | 0.180 |
Why?
|
| Gene Targeting | 1 | 2002 | 16 | 0.180 |
Why?
|
| Salaries and Fringe Benefits | 2 | 2014 | 9 | 0.180 |
Why?
|
| Myocardium | 3 | 2020 | 191 | 0.180 |
Why?
|
| Cullin Proteins | 1 | 2001 | 6 | 0.180 |
Why?
|
| Chromosomes | 1 | 2001 | 9 | 0.180 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2002 | 60 | 0.180 |
Why?
|
| Reimbursement Mechanisms | 4 | 1986 | 13 | 0.180 |
Why?
|
| Cells, Cultured | 5 | 2020 | 820 | 0.170 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2018 | 31 | 0.170 |
Why?
|
| Health Services Research | 3 | 2009 | 81 | 0.170 |
Why?
|
| Genome | 3 | 2014 | 38 | 0.170 |
Why?
|
| Receptors, Peptide | 2 | 2019 | 6 | 0.170 |
Why?
|
| Seminiferous Tubules | 1 | 2000 | 3 | 0.170 |
Why?
|
| Evolution, Molecular | 5 | 2005 | 38 | 0.170 |
Why?
|
| Polymorphism, Genetic | 7 | 2001 | 183 | 0.170 |
Why?
|
| Ifosfamide | 1 | 2020 | 6 | 0.160 |
Why?
|
| Prodrugs | 1 | 2020 | 16 | 0.160 |
Why?
|
| Chromosome Deletion | 2 | 1997 | 11 | 0.160 |
Why?
|
| Case-Control Studies | 4 | 2016 | 876 | 0.160 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2020 | 13 | 0.160 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2017 | 64 | 0.160 |
Why?
|
| Phylogeny | 4 | 2004 | 62 | 0.160 |
Why?
|
| Myocytes, Cardiac | 2 | 2017 | 94 | 0.160 |
Why?
|
| Budgets | 2 | 1999 | 9 | 0.160 |
Why?
|
| Conserved Sequence | 3 | 1998 | 20 | 0.160 |
Why?
|
| Hispanic Americans | 1 | 2016 | 930 | 0.160 |
Why?
|
| Carbon Tetrachloride Poisoning | 1 | 2019 | 2 | 0.160 |
Why?
|
| Health Care Rationing | 1 | 1999 | 12 | 0.150 |
Why?
|
| Cell Line | 6 | 2012 | 433 | 0.150 |
Why?
|
| Costs and Cost Analysis | 7 | 1994 | 102 | 0.150 |
Why?
|
| Medicaid | 7 | 2006 | 99 | 0.150 |
Why?
|
| Glutaminase | 1 | 1998 | 2 | 0.150 |
Why?
|
| DNA Probes | 3 | 1988 | 19 | 0.150 |
Why?
|
| DNA Primers | 6 | 2000 | 89 | 0.150 |
Why?
|
| Trans-Activators | 1 | 1998 | 42 | 0.150 |
Why?
|
| Chemokine CCL3 | 1 | 2018 | 5 | 0.140 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2018 | 5 | 0.140 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2018 | 9 | 0.140 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2018 | 9 | 0.140 |
Why?
|
| Cell Nucleus | 2 | 2009 | 105 | 0.140 |
Why?
|
| Kupffer Cells | 1 | 2018 | 10 | 0.140 |
Why?
|
| Cell Proliferation | 2 | 2019 | 602 | 0.140 |
Why?
|
| Liver Diseases | 1 | 2019 | 74 | 0.140 |
Why?
|
| Multigene Family | 1 | 1998 | 50 | 0.140 |
Why?
|
| Nitric Oxide | 2 | 2010 | 111 | 0.140 |
Why?
|
| Clone Cells | 3 | 2011 | 35 | 0.140 |
Why?
|
| Health Care Sector | 1 | 1998 | 18 | 0.140 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 48 | 0.140 |
Why?
|
| Spheroids, Cellular | 4 | 2021 | 38 | 0.140 |
Why?
|
| GTP-Binding Proteins | 1 | 1998 | 24 | 0.140 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2019 | 82 | 0.140 |
Why?
|
| Oocytes | 2 | 2009 | 46 | 0.140 |
Why?
|
| Adaptor Protein Complex 2 | 1 | 2017 | 2 | 0.140 |
Why?
|
| RNA, Messenger | 5 | 2012 | 498 | 0.140 |
Why?
|
| Logistic Models | 3 | 2009 | 783 | 0.130 |
Why?
|
| Oligospermia | 1 | 1997 | 2 | 0.130 |
Why?
|
| Blotting, Southern | 6 | 2000 | 24 | 0.130 |
Why?
|
| Tissue Array Analysis | 1 | 2017 | 36 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2001 | 42 | 0.130 |
Why?
|
| Interleukin-6 | 1 | 2018 | 240 | 0.130 |
Why?
|
| Crosses, Genetic | 3 | 2005 | 20 | 0.130 |
Why?
|
| Automation | 1 | 2017 | 30 | 0.130 |
Why?
|
| Androgens | 1 | 2017 | 28 | 0.130 |
Why?
|
| Exosomes | 1 | 2017 | 44 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 3 | 2007 | 208 | 0.130 |
Why?
|
| Apoptosis | 3 | 2015 | 362 | 0.130 |
Why?
|
| Cryopreservation | 1 | 2017 | 57 | 0.130 |
Why?
|
| Nuclear Transfer Techniques | 2 | 2014 | 9 | 0.130 |
Why?
|
| Sequence Alignment | 5 | 2013 | 60 | 0.120 |
Why?
|
| Cattle | 2 | 2014 | 108 | 0.120 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 1012 | 0.120 |
Why?
|
| Liver, Artificial | 1 | 2016 | 5 | 0.120 |
Why?
|
| Facility Regulation and Control | 1 | 1996 | 1 | 0.120 |
Why?
|
| Biological Assay | 1 | 2016 | 18 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 255 | 0.120 |
Why?
|
| Adult | 8 | 2021 | 9561 | 0.120 |
Why?
|
| Models, Genetic | 3 | 2001 | 94 | 0.120 |
Why?
|
| Sex Chromosomes | 3 | 2000 | 4 | 0.120 |
Why?
|
| Health Care Reform | 1 | 1996 | 44 | 0.120 |
Why?
|
| Brain | 3 | 2012 | 946 | 0.120 |
Why?
|
| Cytokines | 2 | 2019 | 247 | 0.120 |
Why?
|
| Endothelial Cells | 1 | 2016 | 197 | 0.110 |
Why?
|
| Pseudogenes | 3 | 2000 | 5 | 0.110 |
Why?
|
| Health Services Needs and Demand | 3 | 1996 | 80 | 0.110 |
Why?
|
| Receptors, Cell Surface | 3 | 2004 | 69 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 4 | 1998 | 199 | 0.110 |
Why?
|
| Homeodomain Proteins | 1 | 2014 | 52 | 0.110 |
Why?
|
| Hominidae | 1 | 1994 | 4 | 0.110 |
Why?
|
| Meiosis | 6 | 2007 | 33 | 0.110 |
Why?
|
| Deoxyribonucleases | 1 | 2014 | 2 | 0.110 |
Why?
|
| Blastocyst | 1 | 2014 | 8 | 0.110 |
Why?
|
| Chromosomes, Artificial, Yeast | 3 | 2001 | 6 | 0.110 |
Why?
|
| Milk | 1 | 2014 | 16 | 0.110 |
Why?
|
| Nurses | 1 | 2014 | 15 | 0.110 |
Why?
|
| Health Services Accessibility | 2 | 1991 | 252 | 0.110 |
Why?
|
| Seminal Plasma Proteins | 1 | 2013 | 2 | 0.110 |
Why?
|
| Time Factors | 3 | 2009 | 2183 | 0.100 |
Why?
|
| Gene Rearrangement | 3 | 2004 | 11 | 0.100 |
Why?
|
| Mice, Inbred Strains | 6 | 2001 | 46 | 0.100 |
Why?
|
| Kidney | 2 | 2015 | 520 | 0.100 |
Why?
|
| Gene Silencing | 1 | 2013 | 45 | 0.100 |
Why?
|
| Long-Term Care | 4 | 1997 | 25 | 0.100 |
Why?
|
| Transfection | 1 | 2014 | 184 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2013 | 90 | 0.100 |
Why?
|
| H-2 Antigens | 2 | 1983 | 7 | 0.100 |
Why?
|
| GATA4 Transcription Factor | 1 | 2013 | 2 | 0.100 |
Why?
|
| Enterocytes | 1 | 2013 | 7 | 0.100 |
Why?
|
| Exercise Test | 1 | 2014 | 223 | 0.100 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2013 | 16 | 0.100 |
Why?
|
| Genotype | 5 | 2012 | 731 | 0.100 |
Why?
|
| Epistasis, Genetic | 1 | 2013 | 44 | 0.100 |
Why?
|
| Cyclooxygenase 2 | 1 | 2013 | 50 | 0.100 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2013 | 43 | 0.100 |
Why?
|
| Gonadal Dysgenesis | 1 | 1992 | 1 | 0.100 |
Why?
|
| Marsupialia | 1 | 1992 | 1 | 0.100 |
Why?
|
| Models, Econometric | 2 | 2009 | 9 | 0.100 |
Why?
|
| Mutagenesis | 1 | 2012 | 31 | 0.100 |
Why?
|
| Intestinal Mucosa | 1 | 2013 | 73 | 0.100 |
Why?
|
| Hindlimb | 1 | 2012 | 52 | 0.090 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2013 | 28 | 0.090 |
Why?
|
| Motor Neurons | 1 | 2012 | 40 | 0.090 |
Why?
|
| Hydrogels | 3 | 2020 | 126 | 0.090 |
Why?
|
| Organ Size | 2 | 2005 | 219 | 0.090 |
Why?
|
| Minor Histocompatibility Antigens | 4 | 2002 | 6 | 0.090 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2012 | 80 | 0.090 |
Why?
|
| Growth | 1 | 2012 | 6 | 0.090 |
Why?
|
| Homozygote | 3 | 2013 | 58 | 0.090 |
Why?
|
| Growth Plate | 1 | 2012 | 5 | 0.090 |
Why?
|
| Cryptorchidism | 2 | 2002 | 3 | 0.090 |
Why?
|
| Ganglia, Spinal | 1 | 2012 | 67 | 0.090 |
Why?
|
| Insurance Claim Reporting | 2 | 2009 | 3 | 0.090 |
Why?
|
| Histone Demethylases | 4 | 2001 | 8 | 0.090 |
Why?
|
| Heart | 3 | 2017 | 185 | 0.090 |
Why?
|
| Tissue Banks | 1 | 2011 | 14 | 0.090 |
Why?
|
| Mice, Inbred AKR | 3 | 2007 | 4 | 0.090 |
Why?
|
| Health Policy | 2 | 1998 | 93 | 0.090 |
Why?
|
| DNA | 5 | 1994 | 218 | 0.090 |
Why?
|
| Housing for the Elderly | 1 | 1991 | 4 | 0.090 |
Why?
|
| Culture Media, Conditioned | 1 | 2011 | 47 | 0.090 |
Why?
|
| Regeneration | 1 | 2013 | 170 | 0.090 |
Why?
|
| Middle Aged | 6 | 2016 | 12126 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2012 | 83 | 0.090 |
Why?
|
| Chondrocytes | 1 | 2012 | 69 | 0.090 |
Why?
|
| Aging, Premature | 1 | 2011 | 4 | 0.090 |
Why?
|
| Energy Metabolism | 1 | 2012 | 155 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2013 | 212 | 0.090 |
Why?
|
| Urinary Bladder | 1 | 2013 | 183 | 0.090 |
Why?
|
| Adiposity | 1 | 2012 | 198 | 0.090 |
Why?
|
| Skilled Nursing Facilities | 1 | 1991 | 12 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2011 | 94 | 0.080 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 25 | 0.080 |
Why?
|
| Nucleic Acid Hybridization | 6 | 1989 | 19 | 0.080 |
Why?
|
| Single Person | 2 | 1991 | 3 | 0.080 |
Why?
|
| Kruppel-Like Transcription Factors | 2 | 2009 | 16 | 0.080 |
Why?
|
| Cochlear Implants | 1 | 2010 | 2 | 0.080 |
Why?
|
| Hearing Aids | 1 | 2010 | 4 | 0.080 |
Why?
|
| Sex-Determining Region Y Protein | 4 | 2000 | 5 | 0.080 |
Why?
|
| Urinary Bladder Diseases | 1 | 2010 | 20 | 0.080 |
Why?
|
| Mice, Knockout | 3 | 2013 | 453 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 1991 | 197 | 0.080 |
Why?
|
| Management Quality Circles | 1 | 2009 | 1 | 0.080 |
Why?
|
| Sequence Homology, Amino Acid | 6 | 2003 | 70 | 0.080 |
Why?
|
| Protein Denaturation | 1 | 2009 | 11 | 0.080 |
Why?
|
| Rosaniline Dyes | 1 | 2009 | 18 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2009 | 71 | 0.080 |
Why?
|
| Down-Regulation | 2 | 2012 | 134 | 0.080 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2009 | 49 | 0.080 |
Why?
|
| Transduction, Genetic | 1 | 2009 | 42 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2009 | 28 | 0.080 |
Why?
|
| Cloning, Organism | 1 | 2009 | 12 | 0.080 |
Why?
|
| Immunohistochemistry | 3 | 2008 | 497 | 0.080 |
Why?
|
| Phosphoglycerate Kinase | 1 | 2009 | 2 | 0.080 |
Why?
|
| Staining and Labeling | 1 | 2009 | 57 | 0.080 |
Why?
|
| Ribosomal Proteins | 1 | 2009 | 6 | 0.080 |
Why?
|
| Chromosomes, Human, X | 1 | 2009 | 12 | 0.080 |
Why?
|
| Testicular Neoplasms | 1 | 2009 | 15 | 0.080 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2009 | 11 | 0.080 |
Why?
|
| Illinois | 1 | 2009 | 11 | 0.080 |
Why?
|
| Drugs, Generic | 1 | 2009 | 15 | 0.080 |
Why?
|
| Inbreeding | 2 | 2009 | 5 | 0.080 |
Why?
|
| Thymoma | 3 | 1983 | 6 | 0.070 |
Why?
|
| Medicare Part D | 1 | 2009 | 10 | 0.070 |
Why?
|
| Activities of Daily Living | 2 | 1991 | 258 | 0.070 |
Why?
|
| Decision Making | 3 | 1999 | 202 | 0.070 |
Why?
|
| Cell Survival | 3 | 2020 | 280 | 0.070 |
Why?
|
| Workload | 1 | 2009 | 40 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2009 | 59 | 0.070 |
Why?
|
| Exercise | 1 | 2014 | 679 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 576 | 0.070 |
Why?
|
| Drug Utilization | 1 | 2009 | 49 | 0.070 |
Why?
|
| Cooperative Behavior | 1 | 2009 | 83 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 1998 | 37 | 0.070 |
Why?
|
| Age Factors | 1 | 2012 | 1197 | 0.070 |
Why?
|
| Socioeconomic Factors | 2 | 2009 | 436 | 0.070 |
Why?
|
| Professional-Patient Relations | 1 | 2008 | 23 | 0.070 |
Why?
|
| Forecasting | 2 | 1999 | 143 | 0.070 |
Why?
|
| Poverty | 1 | 2009 | 116 | 0.070 |
Why?
|
| Agonistic Behavior | 1 | 2008 | 1 | 0.070 |
Why?
|
| Insurance Coverage | 1 | 2009 | 80 | 0.070 |
Why?
|
| Health Care Surveys | 1 | 2009 | 186 | 0.070 |
Why?
|
| DNA Mutational Analysis | 2 | 2006 | 71 | 0.070 |
Why?
|
| Nursing Services | 1 | 1988 | 1 | 0.070 |
Why?
|
| Economics | 1 | 1988 | 6 | 0.070 |
Why?
|
| Vagina | 1 | 2008 | 59 | 0.070 |
Why?
|
| Ovulation | 1 | 2007 | 7 | 0.070 |
Why?
|
| Adenosine Triphosphatases | 1 | 2007 | 12 | 0.070 |
Why?
|
| Sulfatases | 1 | 1987 | 1 | 0.070 |
Why?
|
| Hyaluronic Acid | 2 | 2020 | 54 | 0.070 |
Why?
|
| Linear Models | 1 | 2009 | 445 | 0.070 |
Why?
|
| Genes | 1 | 1987 | 15 | 0.070 |
Why?
|
| Adenosine Triphosphate | 1 | 2007 | 55 | 0.070 |
Why?
|
| Ovarian Follicle | 1 | 2007 | 29 | 0.070 |
Why?
|
| Monophenol Monooxygenase | 1 | 2007 | 1 | 0.070 |
Why?
|
| Relaxin | 2 | 2004 | 3 | 0.070 |
Why?
|
| Microfluidics | 2 | 2017 | 18 | 0.070 |
Why?
|
| Erectile Dysfunction | 1 | 2007 | 50 | 0.070 |
Why?
|
| Gene Dosage | 2 | 2005 | 35 | 0.070 |
Why?
|
| Data Collection | 6 | 1994 | 185 | 0.070 |
Why?
|
| Neoplasms | 1 | 2014 | 761 | 0.060 |
Why?
|
| Pigmentation | 2 | 2004 | 6 | 0.060 |
Why?
|
| Recombination, Genetic | 2 | 2000 | 23 | 0.060 |
Why?
|
| Two-Hybrid System Techniques | 2 | 2005 | 5 | 0.060 |
Why?
|
| Antigens, Neoplasm | 2 | 1983 | 39 | 0.060 |
Why?
|
| Lung | 3 | 2017 | 265 | 0.060 |
Why?
|
| Gonads | 2 | 2004 | 3 | 0.060 |
Why?
|
| Major Histocompatibility Complex | 2 | 1983 | 16 | 0.060 |
Why?
|
| Equipment Design | 2 | 2017 | 179 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2014 | 1460 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2006 | 98 | 0.060 |
Why?
|
| Alleles | 3 | 2013 | 253 | 0.060 |
Why?
|
| Retroelements | 1 | 2005 | 4 | 0.060 |
Why?
|
| Polyethylene Glycols | 2 | 2016 | 64 | 0.060 |
Why?
|
| Dentinogenesis Imperfecta | 1 | 2005 | 1 | 0.060 |
Why?
|
| Osteogenesis Imperfecta | 1 | 2005 | 1 | 0.060 |
Why?
|
| Alternative Splicing | 2 | 2003 | 32 | 0.060 |
Why?
|
| Cell Division | 2 | 2002 | 94 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2007 | 835 | 0.060 |
Why?
|
| Wnt Proteins | 1 | 2005 | 17 | 0.060 |
Why?
|
| Utilization Review | 2 | 1999 | 17 | 0.060 |
Why?
|
| Diagnosis-Related Groups | 1 | 1985 | 11 | 0.060 |
Why?
|
| Income | 3 | 1991 | 67 | 0.060 |
Why?
|
| Managed Care Programs | 2 | 1999 | 41 | 0.060 |
Why?
|
| Embryonic and Fetal Development | 2 | 2002 | 10 | 0.060 |
Why?
|
| Acoustic Impedance Tests | 1 | 2004 | 4 | 0.060 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2004 | 5 | 0.060 |
Why?
|
| Speech Perception | 1 | 2004 | 5 | 0.060 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2004 | 8 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 88 | 0.050 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2004 | 6 | 0.050 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2004 | 18 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 4 | 2004 | 43 | 0.050 |
Why?
|
| Eye | 1 | 2004 | 16 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2005 | 136 | 0.050 |
Why?
|
| Investments | 1 | 1984 | 3 | 0.050 |
Why?
|
| Thymus Neoplasms | 1 | 1983 | 6 | 0.050 |
Why?
|
| Prevalence | 2 | 2006 | 1002 | 0.050 |
Why?
|
| Extracellular Matrix | 2 | 2016 | 243 | 0.050 |
Why?
|
| Fanconi Anemia | 1 | 2003 | 1 | 0.050 |
Why?
|
| Public Policy | 1 | 1984 | 34 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2004 | 459 | 0.050 |
Why?
|
| Restriction Mapping | 2 | 1994 | 14 | 0.050 |
Why?
|
| Oogenesis | 1 | 2003 | 5 | 0.050 |
Why?
|
| Embryo Loss | 1 | 2002 | 1 | 0.050 |
Why?
|
| Fetal Weight | 1 | 2002 | 6 | 0.050 |
Why?
|
| Genes, Regulator | 1 | 1982 | 5 | 0.050 |
Why?
|
| Species Specificity | 4 | 2005 | 88 | 0.050 |
Why?
|
| National Health Insurance, United States | 1 | 1982 | 4 | 0.050 |
Why?
|
| Oxidoreductases, N-Demethylating | 3 | 1999 | 5 | 0.050 |
Why?
|
| Quality of Life | 1 | 2008 | 961 | 0.050 |
Why?
|
| Histone-Lysine N-Methyltransferase | 3 | 1999 | 27 | 0.050 |
Why?
|
| Models, Animal | 1 | 2003 | 171 | 0.050 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2002 | 9 | 0.050 |
Why?
|
| Genetic Complementation Test | 1 | 2001 | 3 | 0.050 |
Why?
|
| Cell Movement | 1 | 2002 | 171 | 0.050 |
Why?
|
| DNA, Complementary | 3 | 1999 | 30 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2001 | 56 | 0.040 |
Why?
|
| North Carolina | 1 | 2016 | 1546 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 1989 | 475 | 0.040 |
Why?
|
| Chromosome Banding | 1 | 2001 | 2 | 0.040 |
Why?
|
| Physical Chromosome Mapping | 1 | 2001 | 8 | 0.040 |
Why?
|
| Primates | 2 | 1998 | 116 | 0.040 |
Why?
|
| Immunologic Techniques | 1 | 1981 | 1 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 1998 | 29 | 0.040 |
Why?
|
| Busulfan | 1 | 2000 | 4 | 0.040 |
Why?
|
| Collagen | 2 | 2015 | 219 | 0.040 |
Why?
|
| Ubiquitin-Activating Enzymes | 3 | 2000 | 4 | 0.040 |
Why?
|
| Genetic Variation | 2 | 1999 | 246 | 0.040 |
Why?
|
| Cocarcinogenesis | 1 | 2000 | 2 | 0.040 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2000 | 6 | 0.040 |
Why?
|
| Chimera | 1 | 2000 | 10 | 0.040 |
Why?
|
| Protein Binding | 2 | 2017 | 200 | 0.040 |
Why?
|
| Cell Transplantation | 1 | 2000 | 64 | 0.040 |
Why?
|
| Astemizole | 1 | 2020 | 5 | 0.040 |
Why?
|
| Climate | 2 | 1991 | 3 | 0.040 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 1980 | 14 | 0.040 |
Why?
|
| Sex Characteristics | 3 | 1997 | 172 | 0.040 |
Why?
|
| Cell Line, Transformed | 1 | 2019 | 18 | 0.040 |
Why?
|
| Immunogenetics | 1 | 1979 | 1 | 0.040 |
Why?
|
| Haplotypes | 1 | 2000 | 220 | 0.040 |
Why?
|
| Home Nursing | 1 | 1999 | 10 | 0.040 |
Why?
|
| Endonucleases | 1 | 1998 | 3 | 0.040 |
Why?
|
| STAT1 Transcription Factor | 1 | 1998 | 12 | 0.040 |
Why?
|
| Insurance, Health | 1 | 1980 | 97 | 0.040 |
Why?
|
| Cercopithecidae | 1 | 1998 | 10 | 0.040 |
Why?
|
| Africa | 1 | 1998 | 28 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 1999 | 194 | 0.040 |
Why?
|
| Motivation | 1 | 1999 | 110 | 0.040 |
Why?
|
| Mutation, Missense | 2 | 2013 | 51 | 0.040 |
Why?
|
| Rabbits | 2 | 2009 | 192 | 0.040 |
Why?
|
| Regression Analysis | 3 | 2004 | 288 | 0.040 |
Why?
|
| DNA, Recombinant | 2 | 1988 | 7 | 0.040 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 1998 | 5 | 0.040 |
Why?
|
| Hospitals, Public | 1 | 1998 | 5 | 0.040 |
Why?
|
| Virulence | 1 | 2018 | 22 | 0.040 |
Why?
|
| Hospitals, Private | 1 | 1998 | 9 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 1999 | 238 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 1998 | 33 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1998 | 59 | 0.030 |
Why?
|
| Heart Rate | 1 | 2020 | 343 | 0.030 |
Why?
|
| Graft Survival | 1 | 1979 | 313 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 1998 | 60 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 726 | 0.030 |
Why?
|
| Steryl-Sulfatase | 2 | 1987 | 3 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2017 | 36 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 154 | 0.030 |
Why?
|
| HLA-A2 Antigen | 1 | 1997 | 5 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 1998 | 97 | 0.030 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2019 | 182 | 0.030 |
Why?
|
| Child | 2 | 2006 | 2478 | 0.030 |
Why?
|
| Microfibrils | 1 | 2016 | 3 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1997 | 79 | 0.030 |
Why?
|
| Blotting, Northern | 3 | 2005 | 26 | 0.030 |
Why?
|
| Infant | 2 | 2006 | 1083 | 0.030 |
Why?
|
| Gelatin | 1 | 2016 | 29 | 0.030 |
Why?
|
| Community Health Nursing | 1 | 1996 | 1 | 0.030 |
Why?
|
| Contract Services | 1 | 1996 | 1 | 0.030 |
Why?
|
| Single-Payer System | 1 | 1996 | 2 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2006 | 104 | 0.030 |
Why?
|
| Arizona | 1 | 1996 | 8 | 0.030 |
Why?
|
| Negotiating | 1 | 1996 | 7 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2016 | 28 | 0.030 |
Why?
|
| Cysteine | 1 | 1997 | 138 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2016 | 42 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2006 | 1282 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2016 | 39 | 0.030 |
Why?
|
| HLA-B7 Antigen | 1 | 1995 | 2 | 0.030 |
Why?
|
| Molecular Weight | 1 | 1995 | 42 | 0.030 |
Why?
|
| Tissue Survival | 1 | 2015 | 13 | 0.030 |
Why?
|
| Solutions | 1 | 2015 | 36 | 0.030 |
Why?
|
| Urea | 1 | 2015 | 37 | 0.030 |
Why?
|
| Rheology | 1 | 2015 | 32 | 0.030 |
Why?
|
| Sus scrofa | 1 | 2015 | 47 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1995 | 94 | 0.030 |
Why?
|
| Albumins | 1 | 2015 | 44 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 1995 | 99 | 0.030 |
Why?
|
| Calcium | 1 | 2017 | 323 | 0.030 |
Why?
|
| Insurance, Long-Term Care | 1 | 1995 | 1 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 1995 | 77 | 0.030 |
Why?
|
| Exons | 3 | 2000 | 52 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2015 | 42 | 0.030 |
Why?
|
| Erythropoietin | 1 | 2015 | 31 | 0.030 |
Why?
|
| Models, Biological | 1 | 2017 | 392 | 0.030 |
Why?
|
| Kidney Transplantation | 1 | 1979 | 512 | 0.030 |
Why?
|
| Sex Factors | 2 | 2011 | 675 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 60 | 0.030 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1994 | 1 | 0.030 |
Why?
|
| Fibrosis | 1 | 2015 | 122 | 0.030 |
Why?
|
| Length of Stay | 1 | 1996 | 329 | 0.030 |
Why?
|
| Creatinine | 1 | 2015 | 198 | 0.030 |
Why?
|
| Patients | 1 | 2014 | 48 | 0.030 |
Why?
|
| Cardiovascular System | 1 | 2014 | 46 | 0.030 |
Why?
|
| Foreign Professional Personnel | 1 | 1994 | 1 | 0.030 |
Why?
|
| Hospitals, Municipal | 1 | 1994 | 1 | 0.030 |
Why?
|
| Home Care Agencies | 1 | 1994 | 1 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2009 | 1066 | 0.030 |
Why?
|
| Nursing Staff, Hospital | 1 | 1994 | 11 | 0.030 |
Why?
|
| Hospitalization | 1 | 1997 | 488 | 0.030 |
Why?
|
| Regenerative Medicine | 1 | 2016 | 202 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2014 | 150 | 0.030 |
Why?
|
| Isoelectric Focusing | 2 | 1983 | 4 | 0.030 |
Why?
|
| Congenital Abnormalities | 1 | 2013 | 10 | 0.020 |
Why?
|
| Crossing Over, Genetic | 2 | 1992 | 2 | 0.020 |
Why?
|
| Risk Factors | 4 | 2006 | 3974 | 0.020 |
Why?
|
| Abnormalities, Multiple | 1 | 2013 | 28 | 0.020 |
Why?
|
| Epitopes | 3 | 1998 | 24 | 0.020 |
Why?
|
| Karyotyping | 1 | 1992 | 28 | 0.020 |
Why?
|
| Tissue Distribution | 2 | 2004 | 58 | 0.020 |
Why?
|
| DNA, Single-Stranded | 1 | 1992 | 13 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2013 | 69 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 148 | 0.020 |
Why?
|
| Adipose Tissue, Brown | 1 | 2012 | 8 | 0.020 |
Why?
|
| Ion Channels | 1 | 2012 | 24 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2013 | 106 | 0.020 |
Why?
|
| Protein Carbonylation | 1 | 2012 | 2 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2012 | 10 | 0.020 |
Why?
|
| Leptin | 1 | 2012 | 73 | 0.020 |
Why?
|
| Bone Development | 1 | 2012 | 8 | 0.020 |
Why?
|
| Dinucleoside Phosphates | 1 | 1992 | 1 | 0.020 |
Why?
|
| Chromosome Walking | 1 | 1992 | 1 | 0.020 |
Why?
|
| Gene Library | 1 | 1992 | 7 | 0.020 |
Why?
|
| Eating | 1 | 2012 | 74 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1991 | 10 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2012 | 38 | 0.020 |
Why?
|
| Adolescent | 2 | 2006 | 3638 | 0.020 |
Why?
|
| Cell Membrane | 2 | 2005 | 96 | 0.020 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 297 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2012 | 94 | 0.020 |
Why?
|
| Probability | 1 | 1991 | 157 | 0.020 |
Why?
|
| Ataxia | 1 | 2011 | 8 | 0.020 |
Why?
|
| Kyphosis | 1 | 2011 | 11 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 1991 | 57 | 0.020 |
Why?
|
| Wasting Syndrome | 1 | 2011 | 14 | 0.020 |
Why?
|
| Lipids | 1 | 2012 | 229 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 894 | 0.020 |
Why?
|
| Patient Admission | 1 | 1991 | 59 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 163 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2013 | 250 | 0.020 |
Why?
|
| Sarcopenia | 1 | 2011 | 66 | 0.020 |
Why?
|
| Cell Aggregation | 1 | 2009 | 2 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2012 | 494 | 0.020 |
Why?
|
| Introns | 2 | 2000 | 39 | 0.020 |
Why?
|
| Multiprotein Complexes | 1 | 2009 | 19 | 0.020 |
Why?
|
| Labor Unions | 1 | 2009 | 1 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2014 | 636 | 0.020 |
Why?
|
| Metalloproteins | 1 | 1989 | 1 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1989 | 16 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2009 | 68 | 0.020 |
Why?
|
| Gonadal Steroid Hormones | 1 | 1989 | 34 | 0.020 |
Why?
|
| Neurons | 1 | 2012 | 416 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 154 | 0.020 |
Why?
|
| Vaginal Diseases | 1 | 2008 | 7 | 0.020 |
Why?
|
| Elastin | 1 | 2008 | 14 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2009 | 272 | 0.020 |
Why?
|
| Tensile Strength | 1 | 2008 | 56 | 0.020 |
Why?
|
| Polymers | 1 | 2008 | 66 | 0.020 |
Why?
|
| Consumer Advocacy | 1 | 1988 | 3 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 316 | 0.020 |
Why?
|
| Community Health Services | 1 | 1988 | 58 | 0.020 |
Why?
|
| Integrases | 1 | 2007 | 2 | 0.020 |
Why?
|
| Leydig Cells | 1 | 2007 | 3 | 0.020 |
Why?
|
| Biopsy | 1 | 2008 | 245 | 0.020 |
Why?
|
| Rate Setting and Review | 2 | 1994 | 6 | 0.020 |
Why?
|
| Base Composition | 1 | 1987 | 10 | 0.020 |
Why?
|
| 5' Untranslated Regions | 1 | 2007 | 5 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 1307 | 0.020 |
Why?
|
| Arylsulfatases | 1 | 1987 | 1 | 0.020 |
Why?
|
| Growth Differentiation Factor 9 | 1 | 2006 | 1 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 15 | 1 | 2006 | 1 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 1989 | 166 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 1987 | 26 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2007 | 59 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2007 | 80 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 1988 | 147 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2007 | 191 | 0.020 |
Why?
|
| Cell Separation | 1 | 1987 | 90 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2006 | 99 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2007 | 565 | 0.010 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2005 | 5 | 0.010 |
Why?
|
| DNA Restriction Enzymes | 1 | 1985 | 3 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2006 | 128 | 0.010 |
Why?
|
| Disabled Persons | 1 | 1986 | 105 | 0.010 |
Why?
|
| DNA, Mitochondrial | 1 | 1985 | 34 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 45 | 0.010 |
Why?
|
| Obesity | 1 | 2012 | 1152 | 0.010 |
Why?
|
| Choice Behavior | 1 | 1986 | 86 | 0.010 |
Why?
|
| Dichotic Listening Tests | 1 | 2004 | 1 | 0.010 |
Why?
|
| Audiometry, Speech | 1 | 2004 | 2 | 0.010 |
Why?
|
| Connective Tissue | 1 | 2004 | 4 | 0.010 |
Why?
|
| Nipples | 1 | 2004 | 3 | 0.010 |
Why?
|
| Genitalia | 1 | 2004 | 8 | 0.010 |
Why?
|
| Flagella | 1 | 2004 | 1 | 0.010 |
Why?
|
| Mice, Quaking | 1 | 2004 | 1 | 0.010 |
Why?
|
| Comorbidity | 1 | 2006 | 573 | 0.010 |
Why?
|
| Capital Financing | 1 | 1984 | 5 | 0.010 |
Why?
|
| Ownership | 1 | 1984 | 15 | 0.010 |
Why?
|
| Molecular Biology | 1 | 1983 | 7 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 1983 | 16 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1983 | 35 | 0.010 |
Why?
|
| Fanconi Anemia Complementation Group D2 Protein | 1 | 2003 | 1 | 0.010 |
Why?
|
| Fanconi Anemia Complementation Group L Protein | 1 | 2003 | 1 | 0.010 |
Why?
|
| BRCA2 Protein | 1 | 2003 | 3 | 0.010 |
Why?
|
| BRCA1 Protein | 1 | 2003 | 6 | 0.010 |
Why?
|
| Ubiquitin | 1 | 2003 | 18 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2003 | 23 | 0.010 |
Why?
|
| Ohio | 1 | 1983 | 64 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1982 | 5 | 0.010 |
Why?
|
| Insurance Benefits | 1 | 1982 | 5 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2002 | 40 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1982 | 30 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2006 | 1572 | 0.010 |
Why?
|
| Contig Mapping | 1 | 2001 | 3 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2001 | 96 | 0.010 |
Why?
|
| Diethylnitrosamine | 1 | 2000 | 1 | 0.010 |
Why?
|
| Mice, Inbred ICR | 1 | 2000 | 12 | 0.010 |
Why?
|
| Longitudinal Studies | 2 | 1995 | 779 | 0.010 |
Why?
|
| Carcinogens | 1 | 2000 | 35 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2000 | 169 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 1980 | 58 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 1979 | 49 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1979 | 151 | 0.010 |
Why?
|
| Heart Transplantation | 1 | 1979 | 48 | 0.010 |
Why?
|
| Platypus | 1 | 1998 | 1 | 0.010 |
Why?
|
| Mammals | 1 | 1998 | 13 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1980 | 410 | 0.010 |
Why?
|
| RNA Splicing | 1 | 1998 | 8 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 1998 | 20 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1998 | 89 | 0.010 |
Why?
|
| Horses | 1 | 1997 | 15 | 0.010 |
Why?
|
| Fluoridation | 1 | 1977 | 1 | 0.010 |
Why?
|
| Fluorides | 1 | 1977 | 5 | 0.010 |
Why?
|
| Artifacts | 1 | 1997 | 42 | 0.010 |
Why?
|
| Water | 1 | 1977 | 61 | 0.010 |
Why?
|
| Peptides | 1 | 1997 | 125 | 0.010 |
Why?
|
| Cosmids | 1 | 1995 | 2 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 1995 | 9 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1995 | 12 | 0.010 |
Why?
|
| Least-Squares Analysis | 1 | 1995 | 32 | 0.010 |
Why?
|
| Fees and Charges | 1 | 1995 | 14 | 0.010 |
Why?
|
| Insurance Claim Review | 1 | 1995 | 28 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 247 | 0.010 |
Why?
|
| Mice, Inbred CBA | 1 | 1994 | 7 | 0.010 |
Why?
|
| Attitude | 1 | 1995 | 43 | 0.010 |
Why?
|
| Demography | 1 | 1995 | 110 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1995 | 129 | 0.010 |
Why?
|
| Licensure, Nursing | 1 | 1994 | 1 | 0.010 |
Why?
|
| New York City | 1 | 1994 | 14 | 0.010 |
Why?
|
| Personnel Turnover | 1 | 1994 | 3 | 0.010 |
Why?
|
| Graft Rejection | 1 | 1995 | 241 | 0.010 |
Why?
|
| Body Weight | 1 | 1995 | 301 | 0.010 |
Why?
|
| Reimbursement, Incentive | 1 | 1994 | 11 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1994 | 43 | 0.010 |
Why?
|
| Hospital Costs | 1 | 1994 | 49 | 0.010 |
Why?
|
| Program Evaluation | 1 | 1994 | 181 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1994 | 767 | 0.010 |
Why?
|
| Louisiana | 1 | 1977 | 12 | 0.000 |
Why?
|